Market Report -- In Play (DYAX)
December 1, 2009 5:54 PM ET
Dyax announces FDA approval of KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older Co announced that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article